ATHE Alterity Therapeutics Ltd: Prakiraan wutah bathi saben saham kanggo taun ngarep

The annual EPS forecast for Alterity Therapeutics (ATHE) highlights risks stemming from a lack of revenue and a dependence on investments in Parkinson's disease therapies, with -30.70 serving as the current metric level. Business development is constrained by the specific nature of small molecule medical cycles, independent of macroeconomic factors. Hubs in the US and Australia provide stability, while external CDMO plants ensure the continuity of drug development.
Rincian metrik keuangan lan pasar Alterity Therapeutics Ltd. (ATHE)

The prospects of Alterity Therapeutics (ATHE) depend directly on the efficacy of therapies for degenerative brain diseases and the success of final clinical trials. This projection of net profit per share for n+1 reflects analysts' consensus expectations regarding the business's future earnings per ordinary share. This indicator's trend allows for the filtering of market noise, assessing capital stability through the prism of projected profit changes in the next reporting period.